(Q39440638)

12 September 2017

title

CD48 as a novel molecular target for antibody therapy in multiple myeloma (English)

1 reference

12 September 2017

1 reference

Naoki Hosen

1

1 reference

12 September 2017

Hiroyoshi Ichihara

2

1 reference

12 September 2017

Atsuko Mugitani

3

1 reference

12 September 2017

Yasutaka Aoyama

4

1 reference

12 September 2017

Yuki Fukuda

5

1 reference

12 September 2017

Satoshi Kishida

6

1 reference

12 September 2017

Yoshikazu Matsuoka

7

1 reference

12 September 2017

Hiroko Nakajima

8

1 reference

12 September 2017

Manabu Kawakami

9

1 reference

12 September 2017

Tamotsu Yamagami

10

1 reference

12 September 2017

Shigeo Fuji

11

1 reference

12 September 2017

Hiroya Tamaki

12

1 reference

12 September 2017

Takafumi Nakao

13

1 reference

12 September 2017

Sumiyuki Nishida

14

1 reference

12 September 2017

Akihiro Tsuboi

15

1 reference

12 September 2017

Shinsuke Iida

16

1 reference

12 September 2017

Masayuki Hino

17

1 reference

12 September 2017

Yoshihiro Oka

18

1 reference

12 September 2017

Yusuke Oji

19

1 reference

12 September 2017

Haruo Sugiyama

20

1 reference

12 September 2017

language of work or name

English

0 references

publication date

21 November 2011

1 reference

British Journal of Haematology

12 September 2017

published in

1 reference

12 September 2017

volume

156

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

213-224

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Rediscovering alemtuzumab: current and emerging therapeutic roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Two distinct human myeloma cell lines originating from one patient with myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Hu Ly-M3--a human leukocyte antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08941.X

10.1111/J.1365-2141.2011.08941.X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference